Antares Pharma, Inc. (NASDAQ: ATRS) Stock Competitors & Peer Comparison
See ATRS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ATRS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ATRS | $5.59 | +0.18% | 0 | 14.95 | $0.37 | N/A |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
ATRS vs BDX Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas BDX's P/E ratio is 11.62. In terms of profitability, ATRS's ROE is +0.31%, compared to BDX's ROE of +0.05%. Regarding short-term risk, ATRS is less volatile compared to BDX. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
ATRS vs BDXA Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas BDXA's P/E ratio is 45.70. In terms of profitability, ATRS's ROE is +0.31%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, ATRS is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
ATRS vs MDLN Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas MDLN's P/E ratio is 45.06. In terms of profitability, ATRS's ROE is +0.31%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, ATRS is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
ATRS vs WST Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas WST's P/E ratio is 41.19. In terms of profitability, ATRS's ROE is +0.31%, compared to WST's ROE of +0.19%. Regarding short-term risk, ATRS is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
ATRS vs HOLX Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas HOLX's P/E ratio is 31.54. In terms of profitability, ATRS's ROE is +0.31%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, ATRS is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
ATRS vs COO Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas COO's P/E ratio is 15.42. In terms of profitability, ATRS's ROE is +0.31%, compared to COO's ROE of +0.03%. Regarding short-term risk, ATRS is less volatile compared to COO. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
ATRS vs BDXB Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas BDXB's P/E ratio is 7.60. In terms of profitability, ATRS's ROE is +0.31%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, ATRS is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
ATRS vs BAX Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas BAX's P/E ratio is 10.77. In terms of profitability, ATRS's ROE is +0.31%, compared to BAX's ROE of -0.16%. Regarding short-term risk, ATRS is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
ATRS vs ATR Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ATR's P/E ratio is 23.13. In terms of profitability, ATRS's ROE is +0.31%, compared to ATR's ROE of +0.14%. Regarding short-term risk, ATRS is less volatile compared to ATR. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
ATRS vs AVTR Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas AVTR's P/E ratio is 13.46. In terms of profitability, ATRS's ROE is +0.31%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, ATRS is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
ATRS vs RGEN Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas RGEN's P/E ratio is 73.31. In terms of profitability, ATRS's ROE is +0.31%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, ATRS is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
ATRS vs TFX Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas TFX's P/E ratio is 12.32. In terms of profitability, ATRS's ROE is +0.31%, compared to TFX's ROE of -0.28%. Regarding short-term risk, ATRS is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
ATRS vs BLCO Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas BLCO's P/E ratio is 24.88. In terms of profitability, ATRS's ROE is +0.31%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, ATRS is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
ATRS vs STVN Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas STVN's P/E ratio is 31.81. In terms of profitability, ATRS's ROE is +0.31%, compared to STVN's ROE of +0.10%. Regarding short-term risk, ATRS is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
ATRS vs MMSI Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas MMSI's P/E ratio is 19.01. In terms of profitability, ATRS's ROE is +0.31%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, ATRS is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
ATRS vs ICUI Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ICUI's P/E ratio is 19.66. In terms of profitability, ATRS's ROE is +0.31%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, ATRS is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
ATRS vs HAE Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas HAE's P/E ratio is 15.86. In terms of profitability, ATRS's ROE is +0.31%, compared to HAE's ROE of +0.11%. Regarding short-term risk, ATRS is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
ATRS vs XRAY Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas XRAY's P/E ratio is 9.04. In terms of profitability, ATRS's ROE is +0.31%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, ATRS is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
ATRS vs LMAT Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas LMAT's P/E ratio is 37.05. In terms of profitability, ATRS's ROE is +0.31%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, ATRS is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
ATRS vs PLSE Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas PLSE's P/E ratio is -27.48. In terms of profitability, ATRS's ROE is +0.31%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, ATRS is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
ATRS vs ATRC Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, ATRS's ROE is +0.31%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, ATRS is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
ATRS vs BLFS Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas BLFS's P/E ratio is -141.85. In terms of profitability, ATRS's ROE is +0.31%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, ATRS is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
ATRS vs AZTA Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas AZTA's P/E ratio is 60.82. In terms of profitability, ATRS's ROE is +0.31%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, ATRS is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
ATRS vs KMTS Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas KMTS's P/E ratio is -8.92. In terms of profitability, ATRS's ROE is +0.31%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, ATRS is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
ATRS vs STAA Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas STAA's P/E ratio is 41.02. In terms of profitability, ATRS's ROE is +0.31%, compared to STAA's ROE of -0.06%. Regarding short-term risk, ATRS is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
ATRS vs QDEL Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas QDEL's P/E ratio is 11.98. In terms of profitability, ATRS's ROE is +0.31%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, ATRS is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
ATRS vs ATRI Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ATRI's P/E ratio is 64.50. In terms of profitability, ATRS's ROE is +0.31%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, ATRS is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
ATRS vs ANGO Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ANGO's P/E ratio is -34.85. In terms of profitability, ATRS's ROE is +0.31%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, ATRS is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
ATRS vs NNNN Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas NNNN's P/E ratio is 145.38. In terms of profitability, ATRS's ROE is +0.31%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, ATRS is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
ATRS vs OSUR Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas OSUR's P/E ratio is -4.78. In terms of profitability, ATRS's ROE is +0.31%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, ATRS is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
ATRS vs SMTI Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas SMTI's P/E ratio is -426.00. In terms of profitability, ATRS's ROE is +0.31%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, ATRS is less volatile compared to SMTI. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
ATRS vs UTMD Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas UTMD's P/E ratio is 19.86. In terms of profitability, ATRS's ROE is +0.31%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, ATRS is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
ATRS vs INFU Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas INFU's P/E ratio is 23.97. In terms of profitability, ATRS's ROE is +0.31%, compared to INFU's ROE of +0.14%. Regarding short-term risk, ATRS is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
ATRS vs KRMD Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas KRMD's P/E ratio is -95.75. In terms of profitability, ATRS's ROE is +0.31%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, ATRS is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
ATRS vs PDEX Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas PDEX's P/E ratio is 19.34. In terms of profitability, ATRS's ROE is +0.31%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, ATRS is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
ATRS vs MBOT Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas MBOT's P/E ratio is -6.58. In terms of profitability, ATRS's ROE is +0.31%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, ATRS is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
ATRS vs AKYA Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas AKYA's P/E ratio is -1.34. In terms of profitability, ATRS's ROE is +0.31%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, ATRS is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
ATRS vs STSS Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas STSS's P/E ratio is -0.02. In terms of profitability, ATRS's ROE is +0.31%, compared to STSS's ROE of -1.66%. Regarding short-term risk, ATRS is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
ATRS vs DXR Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas DXR's P/E ratio is 27.33. In terms of profitability, ATRS's ROE is +0.31%, compared to DXR's ROE of +0.22%. Regarding short-term risk, ATRS is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
ATRS vs OMIC Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas OMIC's P/E ratio is -0.58. In terms of profitability, ATRS's ROE is +0.31%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, ATRS is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
ATRS vs IGAP Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas IGAP's P/E ratio is -10.52. In terms of profitability, ATRS's ROE is +0.31%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, ATRS is less volatile compared to IGAP. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
ATRS vs NEPH Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas NEPH's P/E ratio is 50.86. In terms of profitability, ATRS's ROE is +0.31%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, ATRS is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
ATRS vs MLSS Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas MLSS's P/E ratio is -6.50. In terms of profitability, ATRS's ROE is +0.31%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, ATRS is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
ATRS vs POCI Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas POCI's P/E ratio is -6.07. In terms of profitability, ATRS's ROE is +0.31%, compared to POCI's ROE of -0.37%. Regarding short-term risk, ATRS is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
ATRS vs SDC Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas SDC's P/E ratio is -0.03. In terms of profitability, ATRS's ROE is +0.31%, compared to SDC's ROE of -1.96%. Regarding short-term risk, ATRS is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
ATRS vs HBIO Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas HBIO's P/E ratio is -16.81. In terms of profitability, ATRS's ROE is +0.31%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, ATRS is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
ATRS vs IVC Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas IVC's P/E ratio is -0.79. In terms of profitability, ATRS's ROE is +0.31%, compared to IVC's ROE of -0.46%. Regarding short-term risk, ATRS is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
ATRS vs RVP Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas RVP's P/E ratio is -2.06. In terms of profitability, ATRS's ROE is +0.31%, compared to RVP's ROE of -0.08%. Regarding short-term risk, ATRS is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
ATRS vs ZJYL Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, ATRS's ROE is +0.31%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, ATRS is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
ATRS vs FEMY Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas FEMY's P/E ratio is -10.25. In terms of profitability, ATRS's ROE is +0.31%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, ATRS is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
ATRS vs RGNT Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas RGNT's P/E ratio is -0.08. In terms of profitability, ATRS's ROE is +0.31%, compared to RGNT's ROE of N/A. Regarding short-term risk, ATRS is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
ATRS vs NSTG Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas NSTG's P/E ratio is -0.03. In terms of profitability, ATRS's ROE is +0.31%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, ATRS is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
ATRS vs NXGL Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas NXGL's P/E ratio is -1.13. In terms of profitability, ATRS's ROE is +0.31%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, ATRS is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
ATRS vs POAI Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas POAI's P/E ratio is -0.03. In terms of profitability, ATRS's ROE is +0.31%, compared to POAI's ROE of -107.05%. Regarding short-term risk, ATRS is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
ATRS vs LUCY Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas LUCY's P/E ratio is -0.39. In terms of profitability, ATRS's ROE is +0.31%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, ATRS is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
ATRS vs MHUA Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas MHUA's P/E ratio is 0.25. In terms of profitability, ATRS's ROE is +0.31%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, ATRS is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
ATRS vs NXGLW Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, ATRS's ROE is +0.31%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, ATRS is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
ATRS vs GMVD Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas GMVD's P/E ratio is -0.01. In terms of profitability, ATRS's ROE is +0.31%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, ATRS is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
ATRS vs GMVDW Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas GMVDW's P/E ratio is N/A. In terms of profitability, ATRS's ROE is +0.31%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, ATRS is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
ATRS vs AVGR Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas AVGR's P/E ratio is -0.05. In terms of profitability, ATRS's ROE is +0.31%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, ATRS is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
ATRS vs LUCYW Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, ATRS's ROE is +0.31%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, ATRS is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
ATRS vs GCTK Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas GCTK's P/E ratio is -0.01. In terms of profitability, ATRS's ROE is +0.31%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, ATRS is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for ATRS.Check GCTK's competition here
Invuity, Inc. (NASDAQ: IVTY)
ATRS vs IVTY Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, IVTY has a market cap of 0. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas IVTY's P/E ratio is -3.80. In terms of profitability, ATRS's ROE is +0.31%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, ATRS is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check IVTY's competition here
Analogic Corporation (NASDAQ: ALOG)
ATRS vs ALOG Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, ALOG has a market cap of 0. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas ALOG's P/E ratio is 40.93. In terms of profitability, ATRS's ROE is +0.31%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, ATRS is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check ALOG's competition here
Apria, Inc. (NASDAQ: APR)
ATRS vs APR Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, APR has a market cap of 0. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas APR's P/E ratio is 22.59. In terms of profitability, ATRS's ROE is +0.31%, compared to APR's ROE of +9.81%. Regarding short-term risk, ATRS is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
ATRS vs IIN Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, IIN has a market cap of 0. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas IIN's P/E ratio is 226.45. In terms of profitability, ATRS's ROE is +0.31%, compared to IIN's ROE of -0.00%. Regarding short-term risk, ATRS is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check IIN's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
ATRS vs HRC Comparison July 2026
Antares Pharma, Inc. (NASDAQ: ATRS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRS stands at 0. In comparison, HRC has a market cap of 0. Regarding current trading prices, ATRS is priced at $5.59 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRS currently has a P/E ratio of 14.95, whereas HRC's P/E ratio is 41.92. In terms of profitability, ATRS's ROE is +0.31%, compared to HRC's ROE of +0.14%. Regarding short-term risk, ATRS is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for ATRS.Check HRC's competition here